Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.
Our own Dr. Brian Koffman interviewed Dr. Nirav Shah, Associate Professor of Medicine at Medical College of Wisconsin, focusing on hematological malignancies. They discussed the latest results from a clinical trial of pirtobrutinib, a new reversible Bruton tyrosine kinase (BTK) inhibitor, for treating Richter transformation.
What follows is our patient-friendly summary of this research: Richter’s syndrome (RS), also known as Richter’s transformation, is a rare complication of chronic lymphocytic leukemia (CLL). It transforms into what is usually an aggressive lymphoma with a dismal prognosis.
In January 2022, CLL Society formally announced the launch of a new Research Program that is devoted to supporting underfunded areas of bench and translational science to make progress in the following four critical areas of unmet needs for those diagnosed with CLL / SLL:
We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.
and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.
Dr. Mato and Dr. Woyach discusses the results of a study looking at which features might predict the future development of Richter’s syndrome in patients treated with ibrutinib.
Richter’s Transformation Richter’s Transformation First described in 1928, Richter’s Transformation (RT), also called Richter’s Syndrome (RS), occurs when CLL / SLL changes into a related but much more aggressive large cell
This research was presented by Dr. Romain Guieze and colleagues at the American Society for Hematology annual meeting which was held December 2021 (ASH 2021).
